Neflamapimod: Ph IIa Study 303 data
The double-blind, U.S. Phase IIa Study 303 in 8 evaluable patients ages 60-85 with mild cognitive impairment (MCI) due to
Gathering data...
The double-blind, U.S. Phase IIa Study 303 in 8 evaluable patients ages 60-85 with mild cognitive impairment (MCI) due to